Skip to content
MoneySatire

Ozempic maker Novo Nordisk names rising stock its top risk

Novo Nordisk set a lower share price as a formal goal and the market began the drop.

1 min read
Late-afternoon sun slants from an upper walkway onto an open trading floor where three figures in shirtsleeves, seen only from behind, stand at terminals with.
"...falling is the strategy, not the side effect,"

a Novo Nordisk planning officer said on Saturday after the firm set its 2030 goals.

The Ozempic maker wants the share price down nine percent a year until the chart looks finished. It calls the wrecks of 1929 and 2008 a useful guide and left a blank line on the slide for the next one. Shares tumbled once investors saw the deck. People who bet on price drops said the only threat left is a rise that would ruin the schedule and force them to admit they were early.

Its promise is weight loss, and the share price is the heaviest thing it still owns.